Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 412

The DOI matches its Crossref record.

Multicenter Phase II Study of Fertility-Sparing Treatment With Medroxyprogesterone Acetate for Endometrial Carcinoma and Atypical Hyperplasia in Young Women

Open access
Ushijima, Kimio, Yahata, Hideaki, Yoshikawa, Hiroyuki, Konishi, Ikuo, Yasugi, Toshiharu, Saito, Toshiaki, Nakanishi, Toru, Sasaki, Hiroshi, Saji, Fumitaka, Iwasaka, Tsuyoshi, Hatae, Masayuki, Kodama, Shoji, Saito, Tsuyoshi, Terakawa, Naoki, Yaegashi, Nobuo, Hiura, Masamichi, Sakamoto, Atsuhiko, Tsuda, Hitoshi, Fukunaga, Masaharu, Kamura, Toshiharu·2007·Journal of Clinical Oncology

Abstract

Purpose: To assess the efficacy of fertility-sparing treatment using medroxyprogesterone acetate (MPA) for endometrial carcinoma (EC) and atypical endometrial hyperplasia (AH) in young women. Patients and Methods: This multicenter prospective study was carried out at 16 institutions in Japan. Twenty-eight patients having EC at presumed stage IA and 17 patients with AH at younger than 40 years of age were enrolled. All patients were given a daily oral dose of 600 mg of MPA with low-dose aspirin. This treatment continued for 26 weeks, as long as the patients responded. Histologic change of endometrial tissue was assessed at 8 and 16 weeks of treatment. Either estrogen-progestin therapy or fertility treatment was provided for the responders after MPA therapy. The primary end point was a pathologic complete response (CR) rate. Toxicity, pregnancy rate, and progression-free interval were secondary end points. Results: CR was found in 55% of EC cases and 82% of AH cases. The overall CR rate was 67%. Neither therapeutic death nor irreversible toxicities were observed; however, two patients had grade 3 body weight gain, and one patient had grade 3 liver dysfunction. During the 3-year follow-up period, 12 pregnancies and seven normal deliveries were achieved after MPA therapy. Fourteen recurrences were found in 30 patients (47%) between 7 and 36 months. Conclusion: The efficacy of fertility-sparing treatment with a high-dose of MPA for EC and AH was proven by this prospective trial. Even in responders, however, close follow-up is required because of the substantial rate of recurrence.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2006.08.8344

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 412

Metadata

Authors
Ushijima, K., Yahata, H., Yoshikawa, H., Konishi, I., Yasugi, T., Saito, T., Nakanishi, T., Sasaki, H., Saji, F., Iwasaka, T., Hatae, M., Kodama, S., Saito, T., Terakawa, N., Yaegashi, N., Hiura, M., Sakamoto, A., Tsuda, H., Fukunaga, M., & Kamura, T.
Venue
Journal of Clinical Oncology
Published
2007-07-01
Volume
25
Issue
19
Pages
2798-2803
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2146896519
Cited by
412
References
0
FWCI
19.24
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multicenter Phase II Study of Fertility-Sparing Treatment With Medroxyprogesterone Acetate for Endometrial Carcinoma and Atypical Hyperplasia in Young Women. https://app.cochat.ai/papers/10.1200/jco.2006.08.8344
The paper
Ushijima, K., Yahata, H., Yoshikawa, H., Konishi, I., Yasugi, T., Saito, T., Nakanishi, T., Sasaki, H., Saji, F., Iwasaka, T., Hatae, M., Kodama, S., Saito, T., Terakawa, N., Yaegashi, N., Hiura, M., Sakamoto, A., Tsuda, H., Fukunaga, M., & Kamura, T. (2007). Multicenter Phase II Study of Fertility-Sparing Treatment With Medroxyprogesterone Acetate for Endometrial Carcinoma and Atypical Hyperplasia in Young Women. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2006.08.8344

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.